Market Lens
Welcome to Market Lens, your fresh take on the financial markets.
Each week, we break down the latest headlines, offer clear analysis of stocks, ETFs, and major trends, and share practical trading strategies and investing tips you can use right away. You’ll get honest conversations about risks and opportunities, plus short educational segments to help you build your financial skills and make smarter decisions.
Tune in to cut through the noise, stay ahead of the markets, and get the edge you need—one episode at a time. Subscribe now and see the market more clearly with Market Lens.
Disclaimer: This podcast by kavout.com is for informational and educational purposes only and does not constitute investment advice. All opinions are those of the hosts and guests. Please consult a qualified financial advisor before making any investment decisions.
Market Lens
GLP-1 Drug Stocks Risk: Medicare Deals vs. 2026 Coverage Exclusion
This episode offers conflicting reports regarding the Trump administration's policy on Medicare coverage for GLP-1 drugs used for weight loss. The first source, an article from Investopedia dated November 2025, claims that a new plan would cover popular drugs like Ozempic and Wegovy for Medicare patients for as little as $50 a month, due to negotiated lower prices with pharmaceutical companies. Conversely, the second source, a Pharmaceutical Technology article from April 2025, states that the CMS finalized its 2026 policy under the Trump administration by declining to expand Medicare coverage for these anti-obesity medications, abandoning a prior Biden administration proposal. Both reports highlight the significant financial stakes for drug manufacturers like Eli Lilly and Novo Nordisk, noting drops in their stock prices following policy announcements. The second source also mentions opposition from payer groups concerned about the excessive costs of the drugs.
Disclaimer: This podcast by kavout.com is for informational and educational purposes only and does not constitute investment advice. All opinions are those of the hosts and guests. Please consult a qualified financial advisor before making any investment decisions.